Krenitsky Pharmaceuticals Inc

Drug discovery and preclinical development, with focus on CNS drugs. A small molecule neuroprotective and neuro-enhancing agent and an improved MAO-A inhibitor are available for license (www.kpi-pharma.com)

Activity:

- Licensing & Business Development
- Research & Development

Product / Technology type(s) covered:

- NCE (new chemical entities)
- Pharmaceuticals / Therapeutics

Therapeutic targets:

- Central nervous system
- Mental Health
- Neurology

Markets Covered

a. HeadQuarter: United States of America

b. Continent(s) active: North America , Europe , Far East

c. Countries active: USA Europe Japan

Corporate data:

Number of Employees: 6

Turnover:

Amount:	Year:	Currency:
0	2001	US Dollar

Year founded: 1995